RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1.
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的工作揭示了由 CHI3L1 介导的肿瘤免疫逃逸的新范式,其作用于细胞毒性机制并阻止颗粒极化。靶向 CHI3L1 可以减轻免疫逃逸并增强抗体和细胞免疫疗法的效果。
自然杀伤(NK)细胞需要功能性的裂解颗粒机制来介导有效的抗肿瘤反应。逃避在免疫突触(IS)处部署的裂解货物可能是癌症进展的关键步骤,其机制尚未明确。
NK细胞抗体依赖性细胞毒性(ADCC)是包括抗HER2曲妥珠单抗在内的一些治疗性抗体临床疗效的主要决定因素。因此,我们筛选了曲妥珠单抗耐药的HER2+乳腺癌患者的血清,以寻找能够抑制NK细胞ADCC的分子。我们使用细胞毒性试验和裂解颗粒机制的共聚焦成像在体外验证了我们的发现,并使用同基因和异种移植小鼠模型在体内进行了验证。
我们发现,Trastuzumab难治性患者的血清可在体外抑制健康NK细胞的ADCC。与应答者和健康对照的血清相比,这些血清中含有高水平的炎症蛋白几丁质酶3样1(CHI3L1)。我们证明,重组CHI3L1可抑制ADCC和NK细胞固有细胞毒性。在机制上,CHI3L1通过阻碍晚期糖基化终产物受体及其下游JNK信号传导,阻止微管组织中心与裂解颗粒沿IS的正确极化。在体内,给予CHI3L1会显著损害对NK细胞敏感肿瘤的控制,而阻断CHI3L1可与ADCC协同作用,治愈携带HER2 +异种移植瘤的小鼠。
Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms.
NK cell antibody-dependent cellular cytotoxicity (ADCC) is a major determinant of the clinical efficacy of some therapeutic antibodies including the anti-HER2 Trastuzumab. Thus, we screened sera of Trastuzumab-resistant HER2 +patients with breast cancer for molecules that could inhibit NK cell ADCC. We validated our findings in vitro using cytotoxicity assays and confocal imaging of the lytic granule machinery and in vivo using syngeneic and xenograft murine models.
We found that sera from Trastuzumab-refractory patients could inhibit healthy NK cell ADCC in vitro. These sera contained high levels of the inflammatory protein chitinase 3-like 1 (CHI3L1) compared with sera from responders and healthy controls. We demonstrate that recombinant CHI3L1 inhibits both ADCC and innate NK cell cytotoxicity. Mechanistically, CHI3L1 prevents the correct polarization of the microtubule-organizing center along with the lytic granules to the IS by hindering the receptor of advanced glycation end-products and its downstream JNK signaling. In vivo, CHI3L1 administration drastically impairs the control of NK cell-sensitive tumors, while CHI3L1 blockade synergizes with ADCC to cure mice with HER2 +xenografts.
Our work highlights a new paradigm of tumor immune escape mediated by CHI3L1 which acts on the cytotoxic machinery and prevents granule polarization. Targeting CHI3L1 could mitigate immune escape and potentiate antibody and cell-based immunotherapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。